Trovagene Broadens Network of Commercial Distributors
Trovagene, Inc. has signed agreements with seven strategic partners across Europe and the Middle East for commercialization of the Trovera™ liquid biopsy tests. This milestone marks the first wave of international distribution agreements for Trovagene's CLIA based liquid biopsy tests for urine and blood samples.
The initial partners will introduce Trovagene's liquid biopsy tests to physicians, laboratories and cancer centers in key regional markets. In addition, these partners will have early access to Trovagene's research use only liquid biopsy kits and systems to distribute to clinical research facilities in Europe, Middle East, Africa and Asia.
These strategic partners include Alliance Global (AGBL) for the Middle East, Africa, Central and South Asia, Instituto Diagnostico Varelli (Italy), Progenetics (Israel), Amplitech (France, Belgium and Switzerland), NM Genomix (Bulgaria and East Europe), Diagnostica Longwood (Spain and Portugal), and Sorgente Genetica (Italy).
"We are excited to announce that physicians and patients in these international markets now have access to our industry leading laboratory developed tests for EGFR, KRAS, and BRAF mutations in urine and blood," said Bill Welch, Chief Executive Officer of Trovagene.
Trovagene is pleased to partner with these premier life science and diagnostic organizations. In addition to the well-established clinical next-generation sequencing and research business channels they have created in their regions, this network also provides the infrastructure for scientific education, training and support of new technologies and future product introductions.
First Ever Online Event Focused on Cannabis ScienceNews
Analytical Cannabis is pleased to announce that the final line-up of speakers for the first ever cannabis science online event, The Science of Cannabis 2017 has been confirmed.READ MORE
Blood Test for Colitis Screening Could Reduce Dependence on ColonoscopyNews
A fast, simple blood test for ulcerative colitis using infrared spectroscopy could provide a cheaper, less invasive alternative for screening compared to colonoscopy, which is now the predominant test.READ MORE
Comments | 0 ADD COMMENT
13th Edition of International Conference on Pediatric Gastroenterology
Aug 02 - Aug 04, 2018